4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 12.8% – Should You Buy?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s stock price rose 12.8% on Wednesday . The company traded as high as $9.75 and last traded at $9.78. Approximately 233,290 shares were traded during trading, a decline of 69% from the average daily volume of 758,013 shares. The stock had previously closed at $8.67.

Analyst Ratings Changes

FDMT has been the subject of a number of research reports. Royal Bank Of Canada upped their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 19th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Jefferies Financial Group restated a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Chardan Capital reissued a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

4D Molecular Therapeutics Stock Performance

The company’s fifty day moving average price is $9.46 and its 200-day moving average price is $9.15. The stock has a market cap of $512.40 million, a P/E ratio of -3.81 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently made changes to their positions in FDMT. AQR Capital Management LLC bought a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth about $46,000. Millennium Management LLC lifted its holdings in 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after buying an additional 213,264 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. American Century Companies Inc. lifted its holdings in 4D Molecular Therapeutics by 11.5% during the 2nd quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after buying an additional 5,026 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after buying an additional 2,284 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.